Related references
Note: Only part of the references are listed.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
C. Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Influence of-308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis
Sandrine Guis et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
D. van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2007)
Association of TNF-alpha-308 G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis:: a meta-analysis
Young Ho Lee et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
SNPStats:: a web tool for the analysis of association studies
Xavier Sole et al.
BIOINFORMATICS (2006)
The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population
H Marotte et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Tumour necrosis factor (TNF)alpha-308 G/G promoter polymorphism and TNF alpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis
M. Cuchacovich et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2006)
A haplotype map of the human genome
D Altshuler et al.
NATURE (2005)
Clinical pharmacokinetics of TNF antagonists: How do they differ?
I Nestorov
SEMINARS IN ARTHRITIS AND RHEUMATISM (2005)
Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients
A Martinez et al.
ARTHRITIS AND RHEUMATISM (2004)
Is there a future for TNF promoter polymorphisms?
JP Bayley et al.
GENES AND IMMUNITY (2004)
Polymorphism at position-308 of the tumor necrosis factor a gene influences outcome of infliximab therapy in rheumatoid arthritis
B Mugnier et al.
ARTHRITIS AND RHEUMATISM (2003)
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis
L Padyukov et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Binding and functional comparisons of two types of tumor necrosis factor antagonists
B Scallon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
P Emery et al.
RHEUMATOLOGY (2000)
Effects of stimulus and cell type on the expression of the - 308 tumour necrosis factor promoter polymorphism
KM Kroeger et al.
CYTOKINE (2000)
Share Paper
